I was looking for 2 comments; on cash burn and sales momentum. I...

I was looking for 2 comments; on cash burn and sales momentum. I got a 25% headcount reduction and a "while maintaining our general sales momentum". While not in a pretty presentation package it is the bear minimum of "enough"!

On the subject of the Aussie distributor I make the following comment; The appointment of an international distributor like Allergan would have put aeroform in the hands of a competitor and jeopardised intellectual property. The benefit may have been higher sales. The downside is the risk to that IP. I highlight that AXP has a 20% share of the Aussie market and the US market is approximately 50 times the size of Australia. While there is significant upside in market share terms in Australia the volumes will always be low. AXP's success is in no way dependent upon Australia.